RE:RE:RE:Everyday we are getting closer and closer to approval Better yet... Quidel, Diasorin and Abbott make up around 14 of 50 tests. Say the other 27 manufacturers with 36 test variations drive $5b a quart between them. Average that out to $125m in sales per test, not manufacturer. And these USD, not Cad.
Quidel's PE Ratio was a 6, based on 80% ($800m) of it $1b quarter was COVID19 tests. So just take 50% profit of average $125m (of 36 tests from 27 otger companies) = $60m profit x PE ratio of 5 (not 6 even though 10%_ 20% of Thrm rev could be Venowave) = $300m... now that gets to a realistic valuation and $1 stock price at minimum on FDA EUA.
it's saliva, it will get exposure, it will drive sales. No more nasal swabs mid turbinate or deep "way the f up there" swabbing.
That's my thinking.